This listing on Euronext Brussels is also part of the clinical development of the company conducting a phase II / III clinical study in Belgium with ADV7103, its main product, for the treatment of cystinuria, a rare nephrological disease.
Paul Michalet, Chief Financial Officer of Advicenne, commented: "We are very pleased with the success of this cross-listing in the Euronext Brussels and Paris markets, which will increase Advicenne's visibility in Europe and increase the liquidity of the stock market."
Clinical Trials (Phases I, II, III)
Phase I: small molecule test in humans to evaluate their safety, tolerance, metabolic and pharmacological properties Phase II: assessment of tolerance and efficacy in several hundred patients to identify side effects. III: evaluation of the overall benefit / risk ratio for several thousand patients.
Copyright 2019 AOF
All rights of reproduction and representation reserved (Legal notice)